Suzhou Highfine Biotech Co Ltd
Suzhou Highfine Biotech maintains a strong liquidity position with a current ratio of 7.08, indicating robust short-term asset coverage over liabilities. However, the company reported negative net cash after subtracting total debt, signaling potential liquidity constraints despite its high current ratio. The price-to-book ratio of 2.67 and a debt-to-equity ratio of 0.03 suggest a relatively conservative capital structure with minimal leverage. Profitability metrics show a return on equity (ROE) of 4.87% and a return on assets (ROA) of 4.32%, both below the typical thresholds for high-margin chemical firms. The gross margin of 33.7% (calculated from gross profit of 203.15 million CNY on revenue of 602.26 million CNY) is in line with industry norms, but the operating margin of 21.6% (130.15 million CNY) and net margin of 19.0% (114.65 million CNY) suggest moderate efficiency in converting revenue to profit. The company's revenue is distributed across multiple product lines, including peptide synthesis reagents, molecular building blocks, and pharmaceutical reagents. While geographic exposure is not explicitly detailed, the company operates in both domestic and overseas markets, indicating a diversified but not fully transparent revenue concentration. Outlook data indicates a projected revenue growth of 12.3% in the current fiscal year and 8.1% in the next, driven by increased demand for peptide synthesis reagents in pharmaceutical and biotech applications. Historical revenue growth has averaged 15.4% annually over the past three years. Risk factors include a medium liquidity risk due to negative net cash and a low dilution risk, with no near-term pressure from share issuance. The company has not disclosed any recent dilutive events, and its diluted shares outstanding remain unchanged at 108 million. Recent filings and transcripts highlight ongoing R&D investments in chiral racemization inhibition reagents and expansion into lipid nanoparticle pharmaceutical reagents. No material legal or regulatory issues were disclosed in the latest 10-K equivalent filing.
Business. Suzhou Highfine Biotech Co Ltd develops, produces, and sells peptide synthesis reagents, including condensation reagents, protection reagents, and chiral racemization inhibition reagents, alongside general molecular building blocks and pharmaceutical reagents, primarily in domestic and overseas markets.
Classification. Suzhou Highfine Biotech is classified under the Basic Materials economic sector, Chemicals business sector, and Commodity Chemicals industry, with a confidence level of 0.92.
- Strong liquidity position with a current ratio of 7.08, but negative net cash after debt.
- Conservative capital structure with a debt-to-equity ratio of 0.03.
- Moderate profitability with ROE of 4.87% and ROA of 4.32%.
- Revenue growth projections of 12.3% and 8.1% for the next two fiscal years.
- Low dilution risk and no recent share issuance activity.
- Diversified product portfolio with a focus on pharmaceutical reagents.
- --
- ## RATIONALES
- Net cash is negative after subtracting total debt.